Bad news continues for CryoLife as tissue company forced to revise 2002 guidance
This article was originally published in Clinica
CryoLife this week revised its guidance downwards for full year 2002, following adverse publicity surrounding its FDA warning letter and investigation (see Clinica No 1016, p 13). Vascular revenues for 2002 will be up 6-8% (compared with earlier predictions of low double-digit growth), and orthopaedics will show similar growth (down from 20%+), said CFO and vice-president Ashley Lee at the company's half-year results announcement. Cardiac revenues will be 4% up.
You may also be interested in...
Senate Finance Committee’s approach to penalize companies for raising WAC list prices is not a ‘price control,’ but a reasonable approach to change the incentives that distort pricing in the supply chain, US HHS Secretary Alex Azar says.
With the pre-GDUFA backlog largely acted upon, the FDA expects ANDA approvals to decrease, but supplement actions to increase in FY 2020 and FY 2021.
February and March inspections deferred unless any are deemed mission critical. China director remains behind as staff evacuate.